These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20395409)

  • 1. A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors.
    Schaertl S; Prime M; Wityak J; Dominguez C; Munoz-Sanjuan I; Pacifici RE; Courtney S; Scheel A; Macdonald D
    J Biomol Screen; 2010 Jun; 15(5):478-87. PubMed ID: 20395409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.
    Prime ME; Andersen OA; Barker JJ; Brooks MA; Cheng RK; Toogood-Johnson I; Courtney SM; Brookfield FA; Yarnold CJ; Marston RW; Johnson PD; Johnsen SF; Palfrey JJ; Vaidya D; Erfan S; Ichihara O; Felicetti B; Palan S; Pedret-Dunn A; Schaertl S; Sternberger I; Ebneth A; Scheel A; Winkler D; Toledo-Sherman L; Beconi M; Macdonald D; Muñoz-Sanjuan I; Dominguez C; Wityak J
    J Med Chem; 2012 Feb; 55(3):1021-46. PubMed ID: 22224594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinnamoyl inhibitors of tissue transglutaminase.
    Pardin C; Pelletier JN; Lubell WD; Keillor JW
    J Org Chem; 2008 Aug; 73(15):5766-75. PubMed ID: 18582115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.
    Choi K; Siegel M; Piper JL; Yuan L; Cho E; Strnad P; Omary B; Rich KM; Khosla C
    Chem Biol; 2005 Apr; 12(4):469-75. PubMed ID: 15850984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors.
    Pardin C; Roy I; Chica RA; Bonneil E; Thibault P; Lubell WD; Pelletier JN; Keillor JW
    Biochemistry; 2009 Apr; 48(15):3346-53. PubMed ID: 19271761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.
    Grosso H; Mouradian MM
    Pharmacol Ther; 2012 Mar; 133(3):392-410. PubMed ID: 22212614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
    Song M; Hwang H; Im CY; Kim SY
    J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis.
    Jang JH; Park JS; Lee TJ; Kwon TK
    Cancer Lett; 2010 Jan; 287(2):224-30. PubMed ID: 19632032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
    Yuan L; Siegel M; Choi K; Khosla C; Miller CR; Jackson EN; Piwnica-Worms D; Rich KM
    Oncogene; 2007 Apr; 26(18):2563-73. PubMed ID: 17099729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the development of tissue transglutaminase (TG2) inhibitors.
    Badarau E; Collighan RJ; Griffin M
    Amino Acids; 2013 Jan; 44(1):119-27. PubMed ID: 22160259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease.
    Mastroberardino PG; Iannicola C; Nardacci R; Bernassola F; De Laurenzi V; Melino G; Moreno S; Pavone F; Oliverio S; Fesus L; Piacentini M
    Cell Death Differ; 2002 Sep; 9(9):873-80. PubMed ID: 12181738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase.
    van der Wildt B; Wilhelmus MM; Bijkerk J; Haveman LY; Kooijman EJ; Schuit RC; Bol JG; Jongenelen CA; Lammertsma AA; Drukarch B; Windhorst AD
    Nucl Med Biol; 2016 Apr; 43(4):232-42. PubMed ID: 27067043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescent probes of tissue transglutaminase reveal its association with arterial stiffening.
    Chabot N; Moreau S; Mulani A; Moreau P; Keillor JW
    Chem Biol; 2010 Oct; 17(10):1143-50. PubMed ID: 21035737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions.
    Badarau E; Wang Z; Rathbone DL; Costanzi A; Thibault T; Murdoch CE; El Alaoui S; Bartkeviciute M; Griffin M
    Chem Biol; 2015 Oct; 22(10):1347-61. PubMed ID: 26456735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reaction profiling of a set of acrylamide-based human tissue transglutaminase inhibitors.
    Jasim MH; Rathbone DL
    J Mol Graph Model; 2018 Jan; 79():157-165. PubMed ID: 29179065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An unprecedented dual antagonist and agonist of human Transglutaminase 2.
    Yi MC; Palanski BA; Quintero SA; Plugis NM; Khosla C
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4922-4926. PubMed ID: 26004580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue transglutaminase-mediated chemoresistance in cancer cells.
    Verma A; Mehta K
    Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor.
    Case A; Stein RL
    Biochemistry; 2007 Jan; 46(4):1106-15. PubMed ID: 17240993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a mechanism-based assay for tissue transglutaminase--results of a high-throughput screen and discovery of inhibitors.
    Case A; Ni J; Yeh LA; Stein RL
    Anal Biochem; 2005 Mar; 338(2):237-44. PubMed ID: 15745743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
    Chrobok NL; Bol JGJM; Jongenelen CA; Brevé JJP; El Alaoui S; Wilhelmus MMM; Drukarch B; van Dam AM
    PLoS One; 2018; 13(4):e0196433. PubMed ID: 29689097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.